0001493152-21-014404.txt : 20210615 0001493152-21-014404.hdr.sgml : 20210615 20210615161033 ACCESSION NUMBER: 0001493152-21-014404 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20210430 FILED AS OF DATE: 20210615 DATE AS OF CHANGE: 20210615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PURE BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001006028 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS CHEMICAL PRODUCTS [2890] IRS NUMBER: 330530289 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14468 FILM NUMBER: 211018635 BUSINESS ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 619-596-8600 MAIL ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCE DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCES DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE MEDICAL SERVICES DATE OF NAME CHANGE: 19960122 10-Q 1 form10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2021

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Commission File Number 001-14468

PURE Bioscience, Inc.

(Exact name of registrant as specified in its charter)

Delaware		33-0530289
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

9669 Hermosa Avenue

Rancho Cucamonga, California

91730

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (619) 596-8600

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ]	Smaller reporting company	[X]

Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

As of June 15, 2021, there were 87,223,141 shares of the registrant’s common stock, $0.01 par value per share, outstanding.

PURE Bioscience, Inc.

Form 10-Q

for the Quarterly Period Ended April 30, 2021

Table of Contents

		Page
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	20
Item 4.	Controls and Procedures	21

PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3.	Defaults Upon Senior Securities	22
Item 4.	Mine Safety Disclosures	22
Item 5.	Other Information	22
Item 6.	Exhibits	23
	Signatures	24

Part I - Financial Information

Item 1. Financial Statements

PURE Bioscience, Inc.

Condensed Consolidated Balance Sheets

	April 30, 2021			July 31, 2020
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	2,819,000		$	3,839,000
Accounts receivable		221,000			1,089,000
Inventories		568,000			547,000
Restricted cash		75,000			75,000
Prepaid expenses		35,000			16,000
Total current assets		3,718,000			5,566,000
Property, plant and equipment, net		747,000			316,000
Patents, net		381,000			441,000
Total assets	$	4,846,000		$	6,323,000
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	557,000		$	1,344,000
Accrued liabilities		142,000			168,000
Loan payable		239,000			—
Total current liabilities		938,000			1,512,000
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding		—			—
Common stock, $0.01 par value: 150,000,000 shares authorized, 87,223,141 shares issued and outstanding at April 30, 2021, and 87,072,951 shares issued and outstanding at July 31, 2020		873,000			871,000
Additional paid-in capital		128,095,000			127,414,000
Accumulated deficit		(125,060,000	)		(123,474,000	)
Total stockholders’ equity		3,908,000			4,811,000
Total liabilities and stockholders’ equity	$	4,846,000		$	6,323,000

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Nine Months Ended						Three months Ended
	April 30,						April 30,
	2021			2020			2021			2020
Net product sales (including related party sales of $124,000 in the three and nine months ended April 30, 2020)	$	2,841,000		$	2,968,000		$	556,000		$	2,221,000
Royalty revenue		227,000			—			5,000			—
Total revenue		3,068,000			2,968,000			561,000			2,221,000
Cost of goods sold		1,250,000			1,270,000			246,000			972,000
Gross profit		1,818,000			1,698,000			315,000			1,249,000
Operating costs and expenses
Selling, general and administrative		3,136,000			2,790,000			1,036,000			690,000
Research and development		265,000			227,000			89,000			85,000
Total operating costs and expenses		3,401,000			3,017,000			1,125,000			775,000
Loss from operations		(1,583,000	)		(1,319,000	)		(810,000	)		474,000
Other income (expense)
Interest expense, net		(3,000	)		(4,000	)		(1,000	)		(1,000	)
Other income, net		—			5,000			—			—
Total other income (expense)		(3,000	)		1,000			(1,000	)		(1,000	)
Net income (loss)	$	(1,586,000	)	$	(1,318,000	)	$	(811,000	)	$	473,000
Net income (loss) per common share-basic	$	(0.02	)	$	(0.02	)	$	(0.01	)	$	0.01
Net income (loss) per common share-diluted	$	(0.02	)	$	(0.02	)	$	(0.01	)	$	0.01
Weighted average shares-basic		87,157,857			80,634,951			87,223,141			83,979,076
Weighted average shares-diluted		87,157,857			80,634,951			87,223,141			85,702,650

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

	Nine Months Ended April 30, 2021													Nine Months Ended April 30, 2020
	Common Stock				Additional Paid-In			Accumulated			Total Stockholders’			Common Stock				Additional Paid-In			Accumulated			Total Stockholders’
	Shares		Amount		Capital			Deficit			Equity			Shares		Amount		Capital			Deficit			Equity
Balances at beginning of period		87,072,951	$	871,000	$	127,414,000		$	(123,474,000	)	$	4,811,000			76,732,334	$	768,000	$	123,900,000		$	(123,478,000	)	$	1,190,000
Issuance of common stock in private placements, net		—		—		—			—			—			9,758,619		97,000		2,733,000			—			2,830,000
Share-based compensation expense - stock options		—		—		621,000			—			621,000			—		—		382,000			—			382,000
Share-based compensation expense - restricted stock units		—		—		62,000			—			62,000			—		—		211,000			—			211,000
Issuance of common stock upon the exercise of stock options		150,190		2,000		(2,000	)		—			—			—		—		—			—			—
Issuance of common stock for vested restricted stock units		—		—		—			—			—			400,000		4,000		(4,000	)		—			—
Net loss		—		—		—			(1,586,000	)		(1,586,000	)		—		—		—			(1,318,000	)		(1,318,000	)
Balances at end of period (Unaudited)		87,223,141	$	873,000	$	128,095,000		$	(125,060,000	)	$	3,908,000			86,890,953	$	869,000	$	127,222,000		$	(124,796,000	)	$	3,295,000

	Three Months Ended April 30, 2021												Three Months Ended April 30, 2020
	Common Stock				Additional Paid-In		Accumulated			Total Stockholders’			Common Stock				Additional Paid-In		Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Equity			Shares		Amount		Capital		Deficit			Equity
Balances at beginning of period (Unaudited)		87,223,141	$	873,000	$	127,882,000	$	(124,249,000	)	$	4,506,000			79,994,402	$	800,000	$	125,245,000	$	(125,269,000	)	$	776,000
Issuance of common stock in private placements, net														6,896,551		69,000		1,931,000		—			2,000,000
Share-based compensation expense - stock options		—		—		193,000		—			193,000			—		—		46,000		—			46,000
Share-based compensation expense - restricted stock units		—		—		20,000		—			20,000			—		—		—		—			—
Issuance of common stock upon the exercise of stock options		—		—		—		—			—			—		—		—		—			—
Net (loss) income		—		—		—		(811,000	)		(811,000	)		—		—		—		473,000			473,000
Balances at end of period (Unaudited)		87,223,141	$	873,000	$	128,095,000	$	(125,060,000	)	$	3,908,000			86,890,953	$	869,000	$	127,222,000	$	(124,796,000	)	$	3,295,000

PURE Bioscience, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended
	April 30,
	2021			2020
Operating activities
Net loss	$	(1,586,000	)	$	(1,318,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		683,000			593,000
Amortization of stock issued for services		—			4,000
Depreciation and amortization		133,000			145,000
Changes in operating assets and liabilities:
Accounts receivable		868,000			(1,234,000	)
Inventories		(21,000	)		(105,000	)
Prepaid expenses		(19,000	)		4,000
Accounts payable and accrued liabilities		(813,000	)		753,000
Deferred rent		—			(4,000	)
Net cash used in operating activities		(755,000	)		(1,162,000	)
Investing activities
Purchases of property, plant and equipment		(504,000	)		(44,000	)
Net cash used in investing activities		(504,000	)		(44,000	)
Financing activities
Net proceeds from the sale of common stock		—			2,830,000
Net proceeds from payroll protection program loan		239,000			—
Net cash provided by financing activities		239,000			2,830,000
Net decrease and increase in cash, cash equivalents, and restricted cash		(1,020,000	)		1,624,000
Cash, cash equivalents, and restricted cash at beginning of period		3,914,000			473,000
Cash, cash equivalents, and restricted cash at end of period	$	2,894,000		$	2,097,000

Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	2,819,000		$	2,022,000
Restricted cash	$	75,000		$	75,000
Total cash, cash equivalents and restricted cash	$	2,894,000		$	2,097,000
Supplemental disclosure of non-cash activities
Cash paid for taxes	$	—		$	2,000

See accompanying notes.

PURE Bioscience, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended April 30, 2021 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2021. The July 31, 2020 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2020 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 8, 2020.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

2. Liquidity

We have a history of recurring losses, and as of April 30, 2021 we have incurred a cumulative net loss of $125,060,000. During the nine months ended April 30, 2021, we recorded a net loss of $1,586,000 on recorded net revenue of $3,068,000. In addition, we used $1,259,000 in operating and investing activities resulting in a cash balance of $2,819,000. Based on current projections, we believe our available cash on-hand, our current efforts to market and sell our products, and our ability to significantly reduce expenses, will provide sufficient cash resources to satisfy our operational needs, for at least one year from the date these financial statements are issued.

Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

3. Significant Accounting Policies

Revenue Recognition

We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control^® as a direct food contact processing aid.

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.

Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.

Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.

Variable Consideration

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Net Loss Per Share

Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2021 and 2020, stock options, warrants and shares issuable under restricted stock unit awards of 10,358,765 and 10,410,890, respectively, have been excluded from the computation of diluted shares outstanding.

Inventory

Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Inventories consist of the following:

	April 30, 2021		July 31, 2020
Raw materials	$	23,000	$	17,000
Finished goods		545,000		530,000
	$	568,000	$	547,000

Share-Based Compensation

We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

Impairment of Long-Lived Assets

In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and nine months ended April 30, 2021 and 2020, no impairment of long-lived assets was indicated or recorded.

Concentrations

Gross product sales. For the three months ended April 30, 2021, three individual customers accounted for 25%, 12% and 11% of our net product sales. For the nine months ended April 30, 2021, two customers accounted for 18% and 10% of our net product sales, respectively. For the three months ended April 30, 2020, two customers accounted for 22% and 11% of our net product sales, respectively. For the nine months ended April 30, 2020, two customers accounted for 17% and 12% of our net product sales, respectively.

Accounts receivable. As of April 30, 2021, we had accounts receivable from three customers that comprised 22%, 15% and 13% of total accounts receivable, respectively. As of April 30, 2020, we had accounts receivable from three customers that comprised of 17%, 11% and 10% of total accounts receivable, respectively.

Purchases. For the three months ended April 30, 2021, two vendors accounted for 23% and 12% of our purchases, respectively. For the nine months ended April 30, 2021, one vendor accounted for 35% of our purchases. For the three months ended April 30, 2020, one vendor accounted for 63% of our purchases. For the nine months ended April 30, 2020, one vendor accounted for 45% of our purchases.

Accounts payable. As of April 30, 2021, our largest three vendors accounted for 36%, 17% and 14% of the total trade accounts payable, respectively. As of April 30, 2020, one vendor accounted for 63% of the total accounts payable.

Segments

We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

4. Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

5. Debt

Receipt of CARES funding

In April 2021, we were funded $239,000 under the Payroll Protection Program (“PPP”) through California Bank and Trust. The PPP was established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. The amount of loan forgiveness will be reduced if, among other reasons, the Company does not maintain staffing or payroll levels. Principal and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan.

6. Stockholders’ Equity

In January 2021, we amended our Articles of Incorporation by increasing our authorized shares to 150,000,000, par value $0.01.

Private Placement Financing – Fiscal Year 2020

On October 2, 2019, we entered into and completed a closing (the “Closing”) of a private placement financing to accredited investors. We raised net proceeds of $830,000 in the Closing of an aggregate of 2,862,068 shares of our common stock at a purchase price of $0.29 per share, the closing sales price of our common stock on the date prior to the Closing. The Shares issued in the private placement financing were issued pursuant to a securities purchase agreement entered into with the investors. Tom Y. Lee and Dale Okuno, each of whom are accredited investors and members of the Company’s Board of Directors invested $290,000 and $250,000, respectively, in the private placement financing. Mr. Lee also serves as the Company’s President and Chief Executive Officer.

The net proceeds to us from the Closing, after deducting the forgoing fees and other offering expenses, were $830,000.

On March 9, 2020, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with various accredited investors with respect to a private placement financing (the “Private Placement”) and simultaneously completed the closing (the “Closing”) of the Private Placement. We raised net proceeds of approximately $2,000,000 in the Private Placement for an aggregate of 6,896,551 shares of our common stock (the “Shares”) at a purchase price of $0.29 per share. The per share purchase price was approved by our Board of Directors on February 24, 2020 and represents a 20% discount to the closing price of the Company’s common stock on that date. Tom Y. Lee, Dale Okuno and Ivan Chen, each of whom are accredited investors and members of the Company’s Board of Directors, invested $650,500, $450,000 and $52,000, respectively, in the Private Placement. Mr. Lee also serves as the Company’s President and Chief Executive Officer.

The net proceeds to us from the Private Placement, after deducting estimated fees and other offering expenses, were approximately $2,000,000.

Warrants

As of April 30, 2021, the Company had 327,765 warrants outstanding with exercise prices ranging from $1.25 to $1.28. All outstanding warrants will expire on or before January 23, 2022. The warrants had an intrinsic value of zero at April 30, 2021.

7. Share-Based Compensation

Restricted Stock Units

The Company issues restricted stock unit awards (“RSUs”) to key management and as compensation for services to consultants and others. The RSUs typically vest over a two-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortizes those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term.

During the nine months ended April 30, 2021, the Company recognized $62,000 of compensation cost relating to the shares vesting during the period. During the nine month period ended April 30, 2020, the Company recognized $49,000 of compensation cost relating to the shares vesting during the period. In addition, the Company accelerated the vesting of 400,000 shares of stock issued to Henry R. Lambert with a remaining value of $162,000 upon his retirement during the period. In total, the Company recognized $211,000 from the vesting of these restricted stock units.

Of the 2,012,500 RSUs outstanding as of April 30, 2021, 1,512,500 RSUs are vested and issuable. These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”.

During the nine months ended April 30, 2021 there were no Restricted Stock Units granted. As of April 30, 2021, there was $165,000 of unrecognized non-cash compensation cost related to the remaining 500,000 RSUs we expect to vest, which will be recognized over a weighted average period of 2.0 years.

A summary of our restricted stock unit activity and related data is as follows:

Outstanding at July 31, 2020			2,012,500
Granted			—
Issued			—
Forfeited			—
Outstanding at April 30, 2021 (of which 1,512,500 have vested and are issuable)			2,012,500

Stock Option Plans

2007 Equity Incentive Plan

In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 shares and extend the term of the 2007 Plan until February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2021, there were approximately 483,000 shares available for issuance under the 2007 Plan.

2017 Equity Incentive Plan

In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by 5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2021, there were approximately 5,321,000 shares available for issuance under the 2017 Plan.

During the nine months ended April 30, 2021, the Compensation Committee of the Board of Directors authorized the issuance of 60,000 stock options to a consultant with a fair value of $48,000 as determined by the Black Scholes option pricing model. The options vest quarterly over one year and carry a five year term.

A summary of our stock option activity is as follows:

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2020		9,432,875		$	0.88	$	5,255,000
Granted		60,000		$	1.30		—
Exercised		(624,375	)	$	0.88		170,000
Expired		(450,000	)	$	1.10		33,000
Cancelled		(400,000	)	$	1.19		—
Outstanding at April 30, 2021		8,018,500		$	0.86	$	401,000

The weighted-average remaining contractual term of options outstanding at April 30, 2021 was 5.0 years.

At April 30, 2021, options to purchase 7,059,125 shares of common stock were exercisable. These options had a weighted-average exercise price of $0.88 and a weighted average remaining contractual term of 4.68 years. The total unrecognized compensation cost related to unvested stock option grants as of April 30, 2021 was approximately $205,000 and the weighted average period over which these grants are expected to vest is 1.03 years.

For the nine months ended April 30, 2021 share-based compensation expense for stock options was $621,000. For the nine months ended April 30, 2020 share-based compensation expense for stock options was $382,000.

During the nine months ended April 30, 2021, there was a net exercise on 624,375 stock options which resulted in the issuance of 150,190 shares of our common stock. As these options were net exercised on a cashless basis, as permitted under the respective option agreements, we did not receive any cash proceeds.

We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Nine Months Ended April 30, 2021			Nine Months Ended April 30, 2020
Volatility		104.93.	%		79.48	%
Risk-free interest rate		0.18	%		1.46	%
Dividend yield		0.0	%		0.0	%
Expected life		2.81 years			5.50 years

Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

8. Related Party Transactions

As of April 30, 2021 and April 30, 2020, accounts payable include $63,600 and $60,000 in board fees due to officers and directors, respectively. Additionally, as of April 30, 2020, $124,000 was due to the company from the sale of product to Harmony Bioscience, Inc. PURE Chairman and CEO Tom Y. Lee is an affiliate of Harmony Bioscience.

9. Commitments and Contingencies

The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we have benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We cannot assure you that such increased demand will continue. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.

Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure.

The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

All references in this Item 2 and elsewhere in this Quarterly Report to “PURE,” “we”, “our,” “us” and the “Company” refer to PURE Bioscience, Inc., a Delaware corporation, and our wholly owned subsidiary, ETI H2O, Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements contained elsewhere in this Quarterly Report.

The discussion in this section contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “would” or “will” or the negative of these terms or other comparable terminology, but their absence does not mean that a statement is not forward-looking. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which could cause our actual results to differ from those projected in any forward-looking statements we make. Several risks and uncertainties we face are discussed in more detail under “Risk Factors” in Part II, Item 1A of this Quarterly Report or in the discussion and analysis below. You should, however, understand that it is not possible to predict or identify all risks and uncertainties and you should not consider the risks and uncertainties identified by us to be a complete set of all potential risks or uncertainties that could materially affect us. You should not place undue reliance on the forward-looking statements we make herein because some or all of them may turn out to be wrong. We undertake no obligation to update any of the forward-looking statements contained herein to reflect future events and developments, except as required by law. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes to those financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are focused on developing and commercializing proprietary antimicrobial products that provide safe and cost-effective solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, we believe SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, non-causticity and the inability of bacteria to form a resistance to it.

We believe there is a significant market opportunity for our safe, non-toxic, non-caustic and effective SDC-based solutions. We currently offer PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control^® as a direct food contact processing aid. In addition to our direct sales efforts with PURE Hard Surface and PURE Control, we market and sell our SDC-based products indirectly through third-party distributors supporting various industries.

Business Strategy

Our goal is to become a sustainable company by commercializing the SDC-based products we have developed with our proprietary technology platform. We are focused on delivering leading antimicrobial products that address food safety risks across the food industry supply chain. Key aspects of our business strategy include:

●

Expanding sales and distribution for our products into the food industry with a focus on a dual track of food safety market opportunities:

		●	*Hard Surface Disinfectant* - commercializing our current EPA registered PURE Hard Surface disinfectant and sanitizer for use in foodservice operations, food manufacturing and food transportation.

		●	*Direct Food Contact* - commercializing FDA approved PURE Control as a direct food contact processing aid for fresh produce; commercializing FDA approved PURE Control as a food processing and intervention aid for food processors treating raw poultry in pre and post on-line reprocessing.

	●	Continuing to grow and establish new strategic alliances to maximize the commercial potential of our technology platform;

	●	Continuing to partner with third parties who are seeking, or intend to seek, approvals to market SDC-based products in markets outside the U.S.

	●	Developing additional proprietary products and applications; and

	●	Protecting and enhancing our intellectual property.

In addition to our current products addressing food safety, we intend to leverage our technology platform through licensing and distribution collaborations in order to develop new products and enter into new markets that could potentially generate multiple sources of revenue.

Financial Overview

This financial overview provides a general description of our revenue and expenses.

Net Product Sales

We contract manufacture and sell SDC-based products for end use, and as a raw material for manufacturing use. We recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Any amounts received prior to satisfying revenue recognition criteria are recorded as deferred revenue. See “Critical Accounting Policies and Estimates – Revenue Recognition”.

Cost of Goods Sold

Cost of goods sold for product sales includes direct and indirect costs to manufacture products, including materials consumed, manufacturing overhead, shipping costs, salaries, benefits, reserved inventory, and related expenses of operations. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Selling, General and Administrative

Selling, general and administrative expense consists primarily of salaries and other related costs for personnel in business development, sales, finance, accounting, information technology, and executive functions. Other selling, general and administrative costs include product marketing, advertising, and trade show costs, as well as public relations and investor relations, facility costs, and legal, accounting and other professional fees.

Research and Development

Our research and development activities are focused on leveraging our technology platform to develop additional proprietary products and applications. Research and development expense consists primarily of personnel and related costs, product registration expenses, and third-party testing. We expense research and development costs as incurred.

Other Income (Expense)

We record interest income, interest expense, the change in derivative liabilities, as well as other non-operating transactions, as other income (expense) in our consolidated statements of operations.

COVID-19

Results of Operations

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our results of operations will be affected for the foreseeable future by several factors that may contribute to these periodic fluctuations, including fluctuations in the buying patterns of our current or potential customers for which we have no visibility, the mix of product sales including a change in the percentage of higher or lower margin formulations and packaging configurations of our products, the cost of product sales including component costs, our inability for any reason to be able to meet demand, the achievement and timing of research and development and regulatory milestones, unforeseen changes in expenses, including non-cash expenses such as the fair value of equity awards granted and the fair value change of derivative liabilities, the calculation of which includes several variable assumptions, and unforeseen manufacturing or supply issues, among other issues. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance. As of the date of this filing, we are not aware of any trends in these factors or events or conditions that we believe are reasonably likely to impact our results of operations in the future.

Comparison of the Three Months Ended April 30, 2021 and 2020

Net Product Sales

Net product sales were $556,000 and $2,221,000 for the three months ended April 30, 2021 and 2020, respectively. The decrease of $1,665,000 was attributable to decreased sales across our distribution and end-user network servicing the food processing, transportation and janitorial industry. Our top three customers accounted for $268,000 of net product sales for the three months ended April 30, 2021. [Add color for COVID last year]

For the three months ended April 30, 2021, three individual customers accounted for 25%, 12% and 11% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

For the three months ended April 30, 2020, two individual customers accounted for 22% and 11% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. The geographic breakdown of net product sales was as follows: 95% U.S., 5% international.

During the three months ended April 30, 2021, we recognized $5,000 in royalties from a nonexclusive third-party distributor.

Cost of Goods Sold

Cost of goods sold was $246,000 and $972,000 for the three months ended April 30, 2021 and 2020, respectively. The decrease of $726,000 was primarily attributable to decreased product sales.

Gross margin as a percentage of net product sales, or gross margin percentage, was 56% for the three months ended April 30, 2021 and 2020, respectively.

Selling, General and Administrative Expense

Selling, general and administrative expense was $1,036,000 and $690,000 for the three months ended April 30, 2021 and 2020, respectively. The increase of $346,000 was primarily attributable to increased personnel and facility costs, as well as, share-based compensation.

Share-based compensation expense, included in selling, general and administrative expense, was $213,000 and $46,000 for the three months ended April 30, 2021 and 2020, respectively. The increase of $167,000 is primarily due to the current year vesting of stock options and restricted stock units granted in the prior year.

Research and Development Expense

Research and development expense, primarily consisting of third-party fees and personnel costs, was $89,000 and $85,000 for the three months ended April 30, 2021 and 2020, respectively.

Comparison of the Nine Months Ended April 30, 2021 and 2020

Net Product Sales

Net product sales were $2,841,000 and $2,968,000 for the nine months ended April 30, 2021 and 2020, respectively. The decrease of $127,000 was attributable to decreased sales across our distribution and end-user network servicing the food processing, transportation and janitorial industry. Our top three customers accounted for $1,019,000 of net product sales for the nine months ended April 30, 2021.

For the nine months ended April 30, 2021, two individual customers accounted for 18% and 10% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

For the nine months ended April 30, 2020, two individual customers accounted for 17% and 12% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. The geographic breakdown of net product sales was as follows: 96% U.S., 4% international.

During the nine months ended April 30, 2021, we recognized $227,000 in royalties from a nonexclusive third-party distributor.

Cost of Goods Sold

Cost of goods sold was $1,250,000 and $1,270,000 for the nine months ended April 30, 2021 and 2020, respectively. The decrease of $20,000 was primarily attributable to decreased product sales.

Gross margin as a percentage of net product sales, or gross margin percentage, was 56% and 57% for the nine months ended April 30, 2021 and 2020, respectively. The decrease in gross margin percentage was primarily attributable to the sale of lower margin formulations and packaging configurations of our products during the nine months ended April 30, 2021, as compared with the prior period.

Selling, General and Administrative Expense

Selling, general and administrative expense was $3,136,000 and $2,790,000 for the nine months ended April 30, 2021 and 2020. The increase of $346,000 was primarily attributable to increased personnel and facility costs, as well as, share-based compensation.

Share-based compensation expense, included in selling, general and administrative expense, was $683,000 and $593,000 for the nine months ended April 30, 2021 and 2020, respectively. The increase of $90,000 is primarily due to the current year vesting of stock options and restricted stock units granted in the prior year.

Research and Development Expense

Research and development expense was $265,000 and $227,000 for the nine months ended April 30, 2021 and 2020, respectively. The increase of $38,000 was primarily attributable to increased spending on third-party research.

Liquidity and Capital Resources

As of April 30, 2021, we had $2,894,000 in cash and cash equivalents compared with $3,914,000 in cash and cash equivalents as of July 31, 2020. The net decrease in cash and cash equivalents was primarily attributable to cash used to fund operations and investments in property, plant and equipment. Additionally, as of April 30, 2021, we had $938,000 of current liabilities, including $557,000 in accounts payable, compared with $1,512,000 of current liabilities, including $1,344,000 in accounts payable as of July 31, 2020. The net decrease in current liabilities was primarily due to trade payables due to our contract manufacture.

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In addition, the condensed consolidated financial statements included in this Quarterly Report have been prepared and presented on a basis assuming we will continue as a going concern. Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether.

We believe the following accounting policies and estimates are critical to aid you in understanding and evaluating our reported financial results.

Revenue Recognition

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Variable Consideration

Share-Based Compensation

We grant equity-based awards under share-based compensation plans or stand-alone contracts. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

Impairment of Long-Lived Assets

Recent Accounting Pronouncements

See Note 4 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

Off Balance Sheet Arrangements

We do not have any off balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act, and as provided in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As required by Rule 13a-15(b) under the Exchange Act, our management conducted an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing evaluation, our Principal Executive Officer and Principal Financial Officer concluded that as of the end of the period covered by this report our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

In connection with the evaluation required by Exchange Act Rule 13a-15(d), our management, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, concluded that there were no changes in our internal controls over financial reporting during the nine months ended April 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II – Other Information

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of our business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and any adverse result in these or other matters may arise from time to time that could harm our business. We are not currently aware of any such legal proceedings or claims to which we or our wholly owned subsidiary is a party or of which any of our property is subject that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Item 1A. Risk Factors

In evaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q, including the risk factor included below, as well as the risk factors disclosed in Item 1A. to Part I of our Annual Report on Form 10-K for the fiscal year ended July 31, 2020, which we filed with the SEC on October 8, 2020 (the “Form 10-K”). Other than the risk factor included below, the risks and uncertainties described in “Item 1A — Risk Factors” of our Form 10-K have not materially changed. Any of the risks discussed in this Quarterly Report on Form 10-Q, including the risk factor included below, or any of the risks disclosed in “Item 1A — Risk Factors” of our Form 10-K, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects.

Risks Related to Our Business and Industry

The currently evolving situation related to the COVID-19 pandemic could adversely affect our business, financial condition and results of operations.

The global outbreak of COVID-19 has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we have benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We cannot assure you that such increased demand will continue. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.

The extent to which the COVID-19 outbreak ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 outbreak has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

3.1		Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)

3.1.1		Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)

3.2		Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)

3.2.1		Amendment to the Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2.1 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)

31.1 *		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 *		Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 *		Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 *		Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101 *		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarterly period ended April 30, 2021, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at April 30, 2021 and July 31, 2020; (ii) Condensed Consolidated Statements of Operations for the three and nine months ended April 30, 2021 and 2020; (iii) Condensed Consolidated Statements of Stockholders’ equity for the three and nine months ended April 30, 2021 and 2020 ;(iv) Condensed Consolidated Statements of Cash Flows for the nine months ended April 30, 2021 and 2020; and (v) Notes to Condensed Consolidated Financial Statements.

104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith.

Signatures

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PURE BIOSCIENCE, INC.

Date: June 15, 2021	By:	/s/ TOM Y. LEE
		Tom Y. Lee, Chief Executive Officer (Principal Executive Officer)

Date: June 15, 2021	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott, Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Tom Y. Lee, Chief Executive Officer of PURE Bioscience, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 15, 2021	By:	/s/ Tom Y. Lee
		Tom Y. Lee
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark S. Elliott, Vice President, Finance and Principal Financial and Accounting Officer of PURE Bioscience, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 15, 2021	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott
		Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and 18 U.S.C. § 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Pure Bioscience, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

	(i)	the accompanying report on Form 10-Q of the Company for the period ended April 30, 2021, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

	(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 15, 2021

By:

/s/ Tom Y. Lee

Tom Y. Lee

Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Pure Bioscience, Inc. and will be retained by Pure Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pure Bioscience, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

	(i)	the accompanying report on Form 10-Q of the Company for the period ended April 30, 2021, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

	(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 15, 2021

By:

/s/ Mark S. Elliott

Mark S. Elliott

Vice President, Finance

(Principal Financial and Accounting Officer)

EX-101.INS 6 pure-20210430.xml XBRL INSTANCE FILE 0001006028 2019-07-31 0001006028 2020-08-01 2021-04-30 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2016-02-01 2016-02-29 0001006028 us-gaap:CommonStockMember 2019-07-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001006028 us-gaap:RetainedEarningsMember 2019-07-31 0001006028 2020-07-31 0001006028 us-gaap:CommonStockMember 2020-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001006028 us-gaap:RetainedEarningsMember 2020-01-31 0001006028 us-gaap:PrivatePlacementMember 2019-10-01 2019-10-02 0001006028 us-gaap:PrivatePlacementMember 2019-10-02 0001006028 us-gaap:PrivatePlacementMember PURE:TomYLeeMember 2019-10-02 0001006028 us-gaap:PrivatePlacementMember PURE:DaleOkunoMember 2019-10-02 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:SharesVestedDuringPeriodMember 2019-08-01 2020-04-30 0001006028 us-gaap:CommonStockMember 2020-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0001006028 us-gaap:RetainedEarningsMember 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerTwoMember 2020-02-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerOneMember 2020-02-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerOneMember 2019-08-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerTwoMember 2019-08-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:CustomerThreeMember 2019-08-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:AccountsPayablesMember PURE:VendorOneMember 2019-08-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:AccountsPayablesMember PURE:VendorThreeMember 2019-08-01 2020-04-30 0001006028 us-gaap:CommonStockMember 2020-07-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001006028 us-gaap:RetainedEarningsMember 2020-07-31 0001006028 2020-04-30 0001006028 PURE:AccreditedInvestorsMember us-gaap:PrivatePlacementMember 2020-03-08 2020-03-09 0001006028 PURE:AccreditedInvestorsMember us-gaap:PrivatePlacementMember 2020-03-09 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2020-07-31 0001006028 2020-01-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2020-07-31 0001006028 2021-04-30 0001006028 2019-08-01 2020-04-30 0001006028 us-gaap:CommonStockMember 2021-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001006028 us-gaap:RetainedEarningsMember 2021-01-31 0001006028 us-gaap:ProductMember 2020-08-01 2021-04-30 0001006028 us-gaap:ProductMember 2019-08-01 2020-04-30 0001006028 us-gaap:RoyaltyMember 2019-08-01 2020-04-30 0001006028 us-gaap:RoyaltyMember 2020-08-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerOneMember 2020-08-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:CustomerTwoMember 2020-08-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:CustomerOneMember 2020-08-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:TwoCustomersMember 2019-08-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:OneCustomerMember 2019-08-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorOneMember 2020-08-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorOneMember 2019-08-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:AccountsPayablesMember PURE:VendorOneMember 2020-08-01 2021-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2020-08-01 2021-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:ConsultantsAndOthersMember 2020-08-01 2021-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:SharesVestedDuringPeriodMember 2020-08-01 2021-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:HenryRLambertMember 2020-08-01 2021-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2021-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:VestedAndIssuableMember 2020-08-01 2021-04-30 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2021-04-30 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2021-01-01 2021-01-31 0001006028 PURE:BoardFeesDuetoOfficersAndDirectorsMember 2021-04-30 0001006028 PURE:BoardFeesDuetoOfficersAndDirectorsMember 2020-04-30 0001006028 2021-06-15 0001006028 us-gaap:ProductMember 2021-02-01 2021-04-30 0001006028 us-gaap:ProductMember 2020-02-01 2020-04-30 0001006028 us-gaap:RoyaltyMember 2021-02-01 2021-04-30 0001006028 us-gaap:RoyaltyMember 2020-02-01 2020-04-30 0001006028 2021-02-01 2021-04-30 0001006028 2020-02-01 2020-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:IndividualCustomerOneMember 2021-02-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:IndividualCustomerTwoMember 2021-02-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember PURE:IndividualCustomerThreeMember 2021-02-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorOneMember 2021-02-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorTwoMember 2021-02-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:PurchasesMember PURE:VendorOneMember 2020-02-01 2020-04-30 0001006028 PURE:ConsultantMember 2021-04-30 0001006028 PURE:ConsultantMember 2020-08-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember PURE:AccountsPayablesMember PURE:VendorTwoMember 2020-08-01 2021-04-30 0001006028 srt:MinimumMember 2021-04-30 0001006028 srt:MaximumMember 2021-04-30 0001006028 us-gaap:CommonStockMember 2020-08-01 2021-04-30 0001006028 us-gaap:CommonStockMember 2019-08-01 2020-04-30 0001006028 us-gaap:CommonStockMember 2021-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2021-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2019-08-01 2020-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001006028 us-gaap:RetainedEarningsMember 2020-08-01 2021-04-30 0001006028 us-gaap:RetainedEarningsMember 2019-08-01 2020-04-30 0001006028 us-gaap:RetainedEarningsMember 2021-04-30 0001006028 us-gaap:CommonStockMember 2021-02-01 2021-04-30 0001006028 us-gaap:CommonStockMember 2020-02-01 2020-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2021-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2020-04-30 0001006028 us-gaap:RetainedEarningsMember 2021-02-01 2021-04-30 0001006028 us-gaap:RetainedEarningsMember 2020-02-01 2020-04-30 0001006028 2021-01-31 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:CustomerTwoMember 2020-08-01 2021-04-30 0001006028 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember PURE:CustomerThreeMember 2020-08-01 2021-04-30 0001006028 PURE:HarmonyBioscienceIncMember 2020-04-30 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2021-04-30 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2020-08-01 2021-04-30 0001006028 us-gaap:PrivatePlacementMember PURE:TomYLeeMember 2020-03-09 0001006028 us-gaap:PrivatePlacementMember PURE:DaleOkunoMember 2020-03-09 0001006028 us-gaap:PrivatePlacementMember PURE:IvenChenMember 2020-03-09 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PayrollProtectionProgramMember 2021-04-30 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PayrollProtectionProgramMember 2021-04-01 2021-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

0.01

5000000

0.01

150000000

PURE BIOSCIENCE, INC. 10-Q 2021-04-30 false Non-accelerated Filer 0001006028 --07-31

3136000

2790000

1036000

690000

265000

227000

89000

85000

3401000

3017000

1125000

775000

-1583000

-1319000

-810000

474000

5000

-3000

1000

-1000

-1586000

-1318000

-811000

473000

-1586000

-1318000

-811000

473000

87223141 true false 2021

621000

382000

193000

46000

621000

382000

193000

46000

62000

211000

20000

62000

211000

20000

473000

3914000

2097000

2894000

3839000

2022000

2819000

Yes Yes false Q3

1344000

557000

63600

60000

124000

3000

4000

1000

75000

2097000

2894000

76732334

79994402

86890953

87072951

87223141

1190000

768000

123900000

-123478000

4811000

800000

125245000

-125269000

869000

127222000

-124796000

871000

127414000

-123474000

3295000

776000

3908000

873000

127882000

-124249000

873000

128095000

-125060000

4506000

830000

2000000

2830000

2000000

97000

2733000

69000

1931000

2862068

6896551

9758619

6896551

150190

1818000

1698000

315000

1249000

4000 -4000 400000

1250000

1270000

246000

972000

150190

624375

3068000

2968000

2841000

2968000

227000

556000

2221000

5000

561000

2221000

87072951

87223141

87072951

87223141

6323000

4846000

441000

381000

316000

747000

5566000

3718000

16000

35000

75000

547000

568000

1089000

221000

1512000

938000

168000

142000

6323000

4846000

-123474000

-125060000

127414000

128095000

871000

873000

2000

-2000

-1020000

1624000

239000

2830000

-504000

-44000

504000

44000

-755000

-1162000

-4000

-813000

753000

19000

-4000

21000

105000

-868000

1234000

133000

145000

4000

683000

593000

2000

1. Basis of Presentation   The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary.   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended April 30, 2021 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2021. The July 31, 2020 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2020 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 8, 2020.   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

3. Significant Accounting Policies   Revenue Recognition   We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">1.</td> <td style="text-align: justify">Identify the contract with the customer</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">2.</td> <td style="text-align: justify">Identify the performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">3.</td> <td style="text-align: justify">Determine the transaction price</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">4.</td> <td style="text-align: justify">Allocate the transaction price to the performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">5.</td> <td style="text-align: justify">Recognize revenue when (or as) each performance obligation is satisfied</td></tr> </table>   Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.   Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid.   Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.   Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.   Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.   Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.   We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.   We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.   The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.   Variable Consideration   We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.   Use of Estimates   The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.   Net Loss Per Share   Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2021 and 2020, stock options, warrants and shares issuable under restricted stock unit awards of 10,358,765 and 10,410,890, respectively, have been excluded from the computation of diluted shares outstanding.   Inventory   Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.   Inventories consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">July 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">23,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">17,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Finished goods</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">545,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">530,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">568,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">547,000</td> <td> </td></tr> </table>   Share-Based Compensation   We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.   Impairment of Long-Lived Assets   In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and nine months ended April 30, 2021 and 2020, no impairment of long-lived assets was indicated or recorded.   Concentrations   Gross product sales. For the three months ended April 30, 2021, three individual customers accounted for 25%, 12% and 11% of our net product sales. For the nine months ended April 30, 2021, two customers accounted for 18% and 10% of our net product sales, respectively. For the three months ended April 30, 2020, two customers accounted for 22% and 11% of our net product sales, respectively. For the nine months ended April 30, 2020, two customers accounted for 17% and 12% of our net product sales, respectively.   Accounts receivable. As of April 30, 2021, we had accounts receivable from three customers that comprised 22%, 15% and 13% of total accounts receivable, respectively. As of April 30, 2020, we had accounts receivable from three customers that comprised of 17%, 11% and 10% of total accounts receivable, respectively.   Purchases. For the three months ended April 30, 2021, two vendors accounted for 23% and 12% of our purchases, respectively. For the nine months ended April 30, 2021, one vendor accounted for 35% of our purchases. For the three months ended April 30, 2020, one vendor accounted for 63% of our purchases. For the nine months ended April 30, 2020, one vendor accounted for 45% of our purchases.   Accounts payable. As of April 30, 2021, our largest three vendors accounted for 36%, 17% and 14% of the total trade accounts payable, respectively. As of April 30, 2020, one vendor accounted for 63% of the total accounts payable.   Segments   We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

4. Recent Accounting Pronouncements   In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

8. Related Party Transactions   As of April 30, 2021 and April 30, 2020, accounts payable include $63,600 and $60,000 in board fees due to officers and directors, respectively. Additionally, as of April 30, 2020, $124,000 was due to the company from the sale of product to Harmony Bioscience, Inc. PURE Chairman and CEO Tom Y. Lee is an affiliate of Harmony Bioscience.

9. Commitments and Contingencies   The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we have benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We cannot assure you that such increased demand will continue. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.   Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure.   The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

Revenue Recognition   We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">1.</td> <td style="text-align: justify">Identify the contract with the customer</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">2.</td> <td style="text-align: justify">Identify the performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">3.</td> <td style="text-align: justify">Determine the transaction price</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">4.</td> <td style="text-align: justify">Allocate the transaction price to the performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">5.</td> <td style="text-align: justify">Recognize revenue when (or as) each performance obligation is satisfied</td></tr> </table>   Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.   Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid.   Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.   Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.   Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.   Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.   We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.   We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.   The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.   Variable Consideration   We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

Use of Estimates   The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Net Loss Per Share   Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2021 and 2020, stock options, warrants and shares issuable under restricted stock unit awards of 10,358,765 and 10,410,890, respectively, have been excluded from the computation of diluted shares outstanding.

Inventory   Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.   Inventories consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">July 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">23,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">17,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Finished goods</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">545,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">530,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">568,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">547,000</td> <td> </td></tr> </table>

Share-Based Compensation   We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

Impairment of Long-Lived Assets   In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and nine months ended April 30, 2021 and 2020, no impairment of long-lived assets was indicated or recorded.

Concentrations   Gross product sales. For the three months ended April 30, 2021, three individual customers accounted for 25%, 12% and 11% of our net product sales. For the nine months ended April 30, 2021, two customers accounted for 18% and 10% of our net product sales, respectively. For the three months ended April 30, 2020, two customers accounted for 22% and 11% of our net product sales, respectively. For the nine months ended April 30, 2020, two customers accounted for 17% and 12% of our net product sales, respectively.   Accounts receivable. As of April 30, 2021, we had accounts receivable from three customers that comprised 22%, 15% and 13% of total accounts receivable, respectively. As of April 30, 2020, we had accounts receivable from three customers that comprised of 17%, 11% and 10% of total accounts receivable, respectively.   Purchases. For the three months ended April 30, 2021, two vendors accounted for 23% and 12% of our purchases, respectively. For the nine months ended April 30, 2021, one vendor accounted for 35% of our purchases. For the three months ended April 30, 2020, one vendor accounted for 63% of our purchases. For the nine months ended April 30, 2020, one vendor accounted for 45% of our purchases.   Accounts payable. As of April 30, 2021, our largest three vendors accounted for 36%, 17% and 14% of the total trade accounts payable, respectively. As of April 30, 2020, one vendor accounted for 63% of the total accounts payable.

Segments   We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

Inventories consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">July 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">23,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">17,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Finished goods</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">545,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">530,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">568,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">547,000</td> <td> </td></tr> </table>

A summary of our restricted stock unit activity and related data is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%">Outstanding at July 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">2,012,500</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Issued</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Forfeited</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding at April 30, 2021 (of which 1,512,500 have vested and are issuable)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,012,500</td> <td> </td></tr> </table>

A summary of our stock option activity is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted- Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Aggregate Intrinsic Value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%">Outstanding at July 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">9,432,875</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.88</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">5,255,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">60,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(624,375</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">0.88</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">170,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Expired</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(450,000</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">1.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">33,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Cancelled</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(400,000</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.19</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding at April 30, 2021</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,018,500</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.86</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">401,000</td> <td> </td></tr> </table>

10358765

10410890

0.11

0.22

0.17

0.12

0.10

0.63

0.14

0.18

0.10

0.22

0.11

0.17

0.35

0.45

0.36

0.25

0.12

0.11

0.23

0.12

0.63

0.17

0.15

0.13

17000

23000

530000

545000

0.29

290000

250000

650500

450000

52000

830000

2000000

P1Y11D

P10Y

P2Y

P10Y

49000

211000

62000

162000

400000

2012500

500000

1512500

These RSUs are issued upon settlement date which is defined as "for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee's Service ceases for any reason and such cessation constitutes a "separation from service" within the meaning of Section 409A of the Code; (iii) the date of Grantee's death or (iv) the date of a Change in Control that constitutes a "change in control event" within the meaning of Section 409A of the Code".

205000

165000

P2Y

P5Y

4000000

5000000

2026-02-04

2031-01-31

483000

5321000

60000

48000

The options vest quarterly over one year and carry a five year term.

7059125

624375

0.88

P4Y8M5D

621000

382000

9432875

8018500

60000

450000

400000

0.88

0.86

1.30

0.88

1.10

1.19

5255000

401000

170000

33000

1.0493

0.7948

0.0018

0.0146

0.00

P2Y9M22D

P5Y6M

327765

1.25

1.28

2022-01-23

239000

-0.02

-0.01

0.01

87157857

80634951

87223141

83979076

87157857

80634951

87223141

85702650

-0.02

-0.01

0.01

124000

239000 239000

5. Debt   Receipt of CARES funding   In April 2021, we were funded $239,000 under the Payroll Protection Program (“PPP”) through California Bank and Trust. The PPP was established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. The amount of loan forgiveness will be reduced if, among other reasons, the Company does not maintain staffing or payroll levels. Principal and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan.

0.20

The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs.

0.010

P2Y

2. Liquidity   We have a history of recurring losses, and as of April 30, 2021 we have incurred a cumulative net loss of $125,060,000. During the nine months ended April 30, 2021, we recorded a net loss of $1,586,000 on recorded net revenue of $3,068,000. In addition, we used $1,259,000 in operating and investing activities resulting in a cash balance of $2,819,000. Based on current projections, we believe our available cash on-hand, our current efforts to market and sell our products, and our ability to significantly reduce expenses, will provide sufficient cash resources to satisfy our operational needs, for at least one year from the date these financial statements are issued.   Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.   Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

6. Stockholders’ Equity   In January 2021, we amended our Articles of Incorporation by increasing our authorized shares to 150,000,000, par value $0.01.   Private Placement Financing – Fiscal Year 2020   On October 2, 2019, we entered into and completed a closing (the “Closing”) of a private placement financing to accredited investors. We raised net proceeds of $830,000 in the Closing of an aggregate of 2,862,068 shares of our common stock at a purchase price of $0.29 per share, the closing sales price of our common stock on the date prior to the Closing. The Shares issued in the private placement financing were issued pursuant to a securities purchase agreement entered into with the investors. Tom Y. Lee and Dale Okuno, each of whom are accredited investors and members of the Company’s Board of Directors invested $290,000 and $250,000, respectively, in the private placement financing. Mr. Lee also serves as the Company’s President and Chief Executive Officer.   The net proceeds to us from the Closing, after deducting the forgoing fees and other offering expenses, were $830,000.   On March 9, 2020, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with various accredited investors with respect to a private placement financing (the “Private Placement”) and simultaneously completed the closing (the “Closing”) of the Private Placement. We raised net proceeds of approximately $2,000,000 in the Private Placement for an aggregate of 6,896,551 shares of our common stock (the “Shares”) at a purchase price of $0.29 per share. The per share purchase price was approved by our Board of Directors on February 24, 2020 and represents a 20% discount to the closing price of the Company’s common stock on that date. Tom Y. Lee, Dale Okuno and Ivan Chen, each of whom are accredited investors and members of the Company’s Board of Directors, invested $650,500, $450,000 and $52,000, respectively, in the Private Placement. Mr. Lee also serves as the Company’s President and Chief Executive Officer.   The net proceeds to us from the Private Placement, after deducting estimated fees and other offering expenses, were approximately $2,000,000.   Warrants   As of April 30, 2021, the Company had 327,765 warrants outstanding with exercise prices ranging from $1.25 to $1.28. All outstanding warrants will expire on or before January 23, 2022. The warrants had an intrinsic value of zero at April 30, 2021.

7. Share-Based Compensation   Restricted Stock Units   The Company issues restricted stock unit awards (“RSUs”) to key management and as compensation for services to consultants and others. The RSUs typically vest over a two-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortizes those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term.   During the nine months ended April 30, 2021, the Company recognized $62,000 of compensation cost relating to the shares vesting during the period. During the nine month period ended April 30, 2020, the Company recognized $49,000 of compensation cost relating to the shares vesting during the period. In addition, the Company accelerated the vesting of 400,000 shares of stock issued to Henry R. Lambert with a remaining value of $162,000 upon his retirement during the period. In total, the Company recognized $211,000 from the vesting of these restricted stock units.   Of the 2,012,500 RSUs outstanding as of April 30, 2021, 1,512,500 RSUs are vested and issuable. These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”.   During the nine months ended April 30, 2021 there were no Restricted Stock Units granted. As of April 30, 2021, there was $165,000 of unrecognized non-cash compensation cost related to the remaining 500,000 RSUs we expect to vest, which will be recognized over a weighted average period of 2.0 years.   A summary of our restricted stock unit activity and related data is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Outstanding at July 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">2,012,500</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Issued</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Outstanding at April 30, 2021 (of which 1,512,500 have vested and are issuable)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,012,500</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Stock Option Plans   2007 Equity Incentive Plan   In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 shares and extend the term of the 2007 Plan until February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2021, there were approximately 483,000 shares available for issuance under the 2007 Plan.   2017 Equity Incentive Plan   In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by 5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2021, there were approximately 5,321,000 shares available for issuance under the 2017 Plan.   During the nine months ended April 30, 2021, the Compensation Committee of the Board of Directors authorized the issuance of 60,000 stock options to a consultant with a fair value of $48,000 as determined by the Black Scholes option pricing model. The options vest quarterly over one year and carry a five year term.   A summary of our stock option activity is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted- Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Aggregate Intrinsic Value</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%">Outstanding at July 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">9,432,875</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.88</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">5,255,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">60,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(624,375</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">0.88</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">170,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Expired</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(450,000</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">1.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">33,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(400,000</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.19</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding at April 30, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,018,500</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.86</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">401,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The weighted-average remaining contractual term of options outstanding at April 30, 2021 was 5.0 years.   At April 30, 2021, options to purchase 7,059,125 shares of common stock were exercisable. These options had a weighted-average exercise price of $0.88 and a weighted average remaining contractual term of 4.68 years. The total unrecognized compensation cost related to unvested stock option grants as of April 30, 2021 was approximately $205,000 and the weighted average period over which these grants are expected to vest is 1.03 years.   For the nine months ended April 30, 2021 share-based compensation expense for stock options was $621,000. For the nine months ended April 30, 2020 share-based compensation expense for stock options was $382,000.   During the nine months ended April 30, 2021, there was a net exercise on 624,375 stock options which resulted in the issuance of 150,190 shares of our common stock. As these options were net exercised on a cashless basis, as permitted under the respective option agreements, we did not receive any cash proceeds.   We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Nine Months Ended April 30, 2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Nine Months Ended April 30, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%">Volatility</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">104.93.</td> <td style="width: 1%">% </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">79.48</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk-free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.18</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">1.46</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life</td> <td> </td> <td> </td> <td style="text-align: right">2.81 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.50 years</td> <td> </td></tr> </table>   Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.   The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.   We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.   The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Nine Months Ended April 30, 2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Nine Months Ended April 30, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%">Volatility</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">104.93.</td> <td style="width: 1%">% </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">79.48</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk-free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.18</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">1.46</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life</td> <td> </td> <td> </td> <td style="text-align: right">2.81 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.50 years</td> <td> </td></tr> </table>

EX-101.SCH 7 pure-20210430.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Significant Accounting Policies - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pure-20210430_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 pure-20210430_def.xml XBRL DEFINITION FILE EX-101.LAB 10 pure-20210430_lab.xml XBRL LABEL FILE Plan Name [Axis] 2007 Equity Incentive Plan [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Sale of Stock [Axis] Private Placement [Member] Title of Individual [Axis] Tom Y Lee [Member] Dale Okuno [Member] Award Type [Axis] Restricted Stock Unit Awards (RSU's) [Member] Vesting [Axis] Shares Vested During Period [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Net Product Sales [Member] Customer [Axis] Customer Two [Member] Customer One [Member] Accounts Receivable [Member] Customer Three [Member] Accounts Payable [Member] Vendor One [Member] Vendor Three [Member] Accredited Investors [Member] 2017 Equity Incentive Plan [Member] Product and Service [Axis] Net Product Sales [Member] Royalty Revenue [Member] Customer Two [Member] Customer One [Member] Purchases [Member] Related Party Transaction [Axis] Consultants and Others [Member] Henry R. Lambert [Member] Scenario [Axis] Vested and Issuable [Member] Board Fees due to Officers and Directors [Member] Individual Customer One [Member] Individual Customer Two [Member] Individual Customer Three [Member] Vendor Two [Member] Consultant [Member] Range [Axis] Minimum [Member] Maximum [Member] Legal Entity [Axis] Harmony Bioscience, Inc [Member] Ivan Chen [Member] Credit Facility [Axis] California Bank and Trust [Member] Debt Instrument [Axis] Payroll Protection Program [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Accounts receivable Inventories Restricted cash Prepaid expenses Total current assets Property, plant and equipment, net Patents, net Total assets Liabilities and stockholders' equity Current liabilities Accounts payable Accrued liabilities Loan payable Total current liabilities Commitments and contingencies Stockholders' equity Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding Common stock, $0.01 par value: 150,000,000 shares authorized, 87,223,141 shares issued and outstanding at April 30, 2021, and 87,072,951 shares issued and outstanding at July 31, 2020 Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Statement [Table] Statement [Line Items] Total revenue Cost of goods sold Gross profit Operating costs and expenses Selling, general and administrative Research and development Total operating costs and expenses Loss from operations Other income (expense) Interest expense, net Other income, net Total other income (expense) Net income (loss) Net income (loss) per common share-basic Net income (loss) per common share-diluted Weighted average shares-basic Weighted average shares-diluted Income Statement [Abstract] Related party sales Balance Balance, shares Issuance of common stock in private placements, net Issuance of common stock in private placements, net, shares Share-based compensation expense - stock options Share-based compensation expense - restricted stock units Issuance of common stock upon the exercise of stock options Issuance of common stock upon the exercise of stock options, shares Issuance of common stock for vested restricted stock units Issuance of common stock for vested restricted stock units, shares Net (loss) income Balance Balance, shares Statement of Cash Flows [Abstract] Operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation Amortization of stock issued for services Depreciation and amortization Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses Accounts payable and accrued liabilities Deferred rent Net cash used in operating activities Investing activities Purchases of property, plant and equipment Net cash used in investing activities Financing activities Net proceeds from the sale of common stock Net proceeds from payroll protection program loan Net cash provided by financing activities Net decrease and increase in cash, cash equivalents, and restricted cash Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Cash and cash equivalents Restricted cash Total cash, cash equivalents and restricted cash Supplemental disclosure of non-cash activities Cash paid for taxes Accounting Policies [Abstract] Basis of Presentation Stock options and warrants Liquidity Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Debt Disclosure [Abstract] Debt Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity Share-based Payment Arrangement [Abstract] Share-Based Compensation Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Revenue Recognition Use of Estimates Net Loss Per Share Inventory Share-Based Compensation Impairment of Long-Lived Assets Concentrations Segments EX-101.PRE 11 pure-20210430_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Apr. 30, 2021	Jun. 15, 2021
Cover [Abstract]
Entity Registrant Name	PURE BIOSCIENCE, INC.
Entity Central Index Key	0001006028
Document Type	10-Q
Document Period End Date	Apr. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		87,223,141
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Apr. 30, 2021	Jul. 31, 2020
Current assets
Cash and cash equivalents	$ 2,819,000	$ 3,839,000
Accounts receivable	221,000	1,089,000
Inventories	568,000	547,000
Restricted cash	75,000	75,000
Prepaid expenses	35,000	16,000
Total current assets	3,718,000	5,566,000
Property, plant and equipment, net	747,000	316,000
Patents, net	381,000	441,000
Total assets	4,846,000	6,323,000
Current liabilities
Accounts payable	557,000	1,344,000
Accrued liabilities	142,000	168,000
Loan payable	239,000
Total current liabilities	938,000	1,512,000
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 150,000,000 shares authorized, 87,223,141 shares issued and outstanding at April 30, 2021, and 87,072,951 shares issued and outstanding at July 31, 2020	873,000	871,000
Additional paid-in capital	128,095,000	127,414,000
Accumulated deficit	(125,060,000)	(123,474,000)
Total stockholders' equity	3,908,000	4,811,000
Total liabilities and stockholders' equity	$ 4,846,000	$ 6,323,000

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Apr. 30, 2021	Jul. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	87,223,141	87,072,951
Common stock, shares outstanding	87,223,141	87,072,951

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Total revenue	$ 561,000	$ 2,221,000	$ 3,068,000	$ 2,968,000
Cost of goods sold	246,000	972,000	1,250,000	1,270,000
Gross profit	315,000	1,249,000	1,818,000	1,698,000
Operating costs and expenses
Selling, general and administrative	1,036,000	690,000	3,136,000	2,790,000
Research and development	89,000	85,000	265,000	227,000
Total operating costs and expenses	1,125,000	775,000	3,401,000	3,017,000
Loss from operations	(810,000)	474,000	(1,583,000)	(1,319,000)
Other income (expense)
Interest expense, net	(1,000)	(1,000)	(3,000)	(4,000)
Other income, net				5,000
Total other income (expense)	(1,000)	(1,000)	(3,000)	1,000
Net income (loss)	$ (811,000)	$ 473,000	$ (1,586,000)	$ (1,318,000)
Net income (loss) per common share-basic	$ (0.01)	$ 0.01	$ (0.02)	$ (0.02)
Net income (loss) per common share-diluted	$ (0.01)	$ 0.01	$ (0.02)	$ (0.02)
Weighted average shares-basic	87,223,141	83,979,076	87,157,857	80,634,951
Weighted average shares-diluted	87,223,141	85,702,650	87,157,857	80,634,951
Net Product Sales [Member]
Total revenue	$ 556,000	$ 2,221,000	$ 2,841,000	$ 2,968,000
Royalty Revenue [Member]
Total revenue	$ 5,000		$ 227,000

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)	3 Months Ended	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2020
Income Statement [Abstract]
Related party sales	$ 124,000	$ 124,000

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Jul. 31, 2019	$ 768,000	$ 123,900,000	$ (123,478,000)	$ 1,190,000
Balance, shares at Jul. 31, 2019	76,732,334
Issuance of common stock in private placements, net	$ 97,000	2,733,000		2,830,000
Issuance of common stock in private placements, net, shares	9,758,619
Share-based compensation expense - stock options		382,000		382,000
Share-based compensation expense - restricted stock units		211,000		211,000
Issuance of common stock for vested restricted stock units	$ 4,000	(4,000)
Issuance of common stock for vested restricted stock units, shares	400,000
Net (loss) income			(1,318,000)	(1,318,000)
Balance at Apr. 30, 2020	$ 869,000	127,222,000	(124,796,000)	3,295,000
Balance, shares at Apr. 30, 2020	86,890,953
Balance at Jan. 31, 2020	$ 800,000	125,245,000	(125,269,000)	776,000
Balance, shares at Jan. 31, 2020	79,994,402
Issuance of common stock in private placements, net	$ 69,000	1,931,000		2,000,000
Issuance of common stock in private placements, net, shares	6,896,551
Share-based compensation expense - stock options		46,000		46,000
Net (loss) income			473,000	473,000
Balance at Apr. 30, 2020	$ 869,000	127,222,000	(124,796,000)	3,295,000
Balance, shares at Apr. 30, 2020	86,890,953
Balance at Jul. 31, 2020	$ 871,000	127,414,000	(123,474,000)	4,811,000
Balance, shares at Jul. 31, 2020	87,072,951
Share-based compensation expense - stock options		621,000		621,000
Share-based compensation expense - restricted stock units		62,000		62,000
Issuance of common stock upon the exercise of stock options	$ 2,000	(2,000)
Issuance of common stock upon the exercise of stock options, shares	150,190
Net (loss) income			(1,586,000)	(1,586,000)
Balance at Apr. 30, 2021	$ 873,000	128,095,000	(125,060,000)	3,908,000
Balance, shares at Apr. 30, 2021	87,223,141
Balance at Jan. 31, 2021	$ 873,000	127,882,000	(124,249,000)	4,506,000
Balance, shares at Jan. 31, 2021	87,223,141
Share-based compensation expense - stock options		193,000		193,000
Share-based compensation expense - restricted stock units		20,000		20,000
Net (loss) income			(811,000)	(811,000)
Balance at Apr. 30, 2021	$ 873,000	$ 128,095,000	$ (125,060,000)	$ 3,908,000
Balance, shares at Apr. 30, 2021	87,223,141

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Operating activities
Net loss	$ (811,000)	$ 473,000	$ (1,586,000)	$ (1,318,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation			683,000	593,000
Amortization of stock issued for services				4,000
Depreciation and amortization			133,000	145,000
Changes in operating assets and liabilities:
Accounts receivable			868,000	(1,234,000)
Inventories			(21,000)	(105,000)
Prepaid expenses			(19,000)	4,000
Accounts payable and accrued liabilities			(813,000)	753,000
Deferred rent				(4,000)
Net cash used in operating activities			(755,000)	(1,162,000)
Investing activities
Purchases of property, plant and equipment			(504,000)	(44,000)
Net cash used in investing activities			(504,000)	(44,000)
Financing activities
Net proceeds from the sale of common stock				2,830,000
Net proceeds from payroll protection program loan			239,000
Net cash provided by financing activities			239,000	2,830,000
Net decrease and increase in cash, cash equivalents, and restricted cash			(1,020,000)	1,624,000
Cash, cash equivalents, and restricted cash at beginning of period			3,914,000	473,000
Cash, cash equivalents, and restricted cash at end of period	2,894,000	2,097,000	2,894,000	2,097,000
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	2,819,000	2,022,000	2,819,000	2,022,000
Restricted cash	75,000	75,000	75,000	75,000
Total cash, cash equivalents and restricted cash	$ 2,894,000	$ 2,097,000	2,894,000	2,097,000
Supplemental disclosure of non-cash activities
Cash paid for taxes				$ 2,000

XML 19 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation

1. Basis of Presentation

XML 20 R9.htm IDEA: XBRL DOCUMENT

Liquidity

9 Months Ended

Apr. 30, 2021

Stock options and warrants

Liquidity

2. Liquidity

XML 21 R10.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Significant Accounting Policies

3. Significant Accounting Policies

Revenue Recognition

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Variable Consideration

Use of Estimates

Net Loss Per Share

Inventory

Inventories consist of the following:

	April 30, 2021		July 31, 2020
Raw materials	$	23,000	$	17,000
Finished goods		545,000		530,000
	$	568,000	$	547,000

Share-Based Compensation

Impairment of Long-Lived Assets

Concentrations

Segments

XML 22 R11.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Apr. 30, 2021

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

4. Recent Accounting Pronouncements

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Debt

9 Months Ended

Apr. 30, 2021

Debt Disclosure [Abstract]

Debt

5. Debt

Receipt of CARES funding

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Apr. 30, 2021

Stockholders' equity

Stockholders' Equity

6. Stockholders’ Equity

In January 2021, we amended our Articles of Incorporation by increasing our authorized shares to 150,000,000, par value $0.01.

Private Placement Financing – Fiscal Year 2020

The net proceeds to us from the Closing, after deducting the forgoing fees and other offering expenses, were $830,000.

The net proceeds to us from the Private Placement, after deducting estimated fees and other offering expenses, were approximately $2,000,000.

Warrants

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Apr. 30, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

7. Share-Based Compensation

Restricted Stock Units

A summary of our restricted stock unit activity and related data is as follows:

Outstanding at July 31, 2020			2,012,500
Granted			—
Issued			—
Forfeited			—
Outstanding at April 30, 2021 (of which 1,512,500 have vested and are issuable)			2,012,500

Stock Option Plans

2007 Equity Incentive Plan

2017 Equity Incentive Plan

A summary of our stock option activity is as follows:

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2020		9,432,875		$	0.88	$	5,255,000
Granted		60,000		$	1.30		—
Exercised		(624,375	)	$	0.88		170,000
Expired		(450,000	)	$	1.10		33,000
Cancelled		(400,000	)	$	1.19		—
Outstanding at April 30, 2021		8,018,500		$	0.86	$	401,000

The weighted-average remaining contractual term of options outstanding at April 30, 2021 was 5.0 years.

	Nine Months Ended April 30, 2021			Nine Months Ended April 30, 2020
Volatility		104.93.	%		79.48	%
Risk-free interest rate		0.18	%		1.46	%
Dividend yield		0.0	%		0.0	%
Expected life		2.81 years			5.50 years

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Apr. 30, 2021

Related Party Transactions

8. Related Party Transactions

XML 27 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Apr. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. Commitments and Contingencies

XML 28 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Revenue Recognition

Revenue Recognition

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Variable Consideration

Use of Estimates

Use of Estimates

Net Loss Per Share

Net Loss Per Share

Inventory

Inventory

Inventories consist of the following:

	April 30, 2021		July 31, 2020
Raw materials	$	23,000	$	17,000
Finished goods		545,000		530,000
	$	568,000	$	547,000

Share-Based Compensation

Share-Based Compensation

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Concentrations

Concentrations

Segments

Segments

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Schedule of Inventories

Inventories consist of the following:

	April 30, 2021		July 31, 2020
Raw materials	$	23,000	$	17,000
Finished goods		545,000		530,000
	$	568,000	$	547,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

9 Months Ended

Apr. 30, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Restricted Stock Activity

A summary of our restricted stock unit activity and related data is as follows:

Outstanding at July 31, 2020			2,012,500
Granted			—
Issued			—
Forfeited			—
Outstanding at April 30, 2021 (of which 1,512,500 have vested and are issuable)			2,012,500

Schedule of Stock Option Activity

A summary of our stock option activity is as follows:

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2020		9,432,875		$	0.88	$	5,255,000
Granted		60,000		$	1.30		—
Exercised		(624,375	)	$	0.88		170,000
Expired		(450,000	)	$	1.10		33,000
Cancelled		(400,000	)	$	1.19		—
Outstanding at April 30, 2021		8,018,500		$	0.86	$	401,000

Schedule of Fair Value Assumptions

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Nine Months Ended April 30, 2021			Nine Months Ended April 30, 2020
Volatility		104.93.	%		79.48	%
Risk-free interest rate		0.18	%		1.46	%
Dividend yield		0.0	%		0.0	%
Expected life		2.81 years			5.50 years

XML 31 R20.htm IDEA: XBRL DOCUMENT

Liquidity (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Liquidity (Details Narrative) - USD ($)	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020	Jul. 31, 2020
Stock options and warrants
Cumulative net loss	$ (125,060,000)		$ (125,060,000)		$ (123,474,000)
Net income (loss)	(811,000)	$ 473,000	(1,586,000)	$ (1,318,000)
Revenue	561,000	2,221,000	3,068,000	2,968,000
Cash balance			(1,020,000)	1,624,000
Cash and cash equivalents	$ 2,819,000	$ 2,022,000	$ 2,819,000	$ 2,022,000	$ 3,839,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Dilutive common share			10,358,765	10,410,890
Impairment of long-lived assets
Customer Concentration Risk [Member] \| Net Product Sales [Member] \| Individual Customer One [Member]
Concentration risk percentage	25.00%
Customer Concentration Risk [Member] \| Net Product Sales [Member] \| Individual Customer Two [Member]
Concentration risk percentage	12.00%
Customer Concentration Risk [Member] \| Net Product Sales [Member] \| Individual Customer Three [Member]
Concentration risk percentage	11.00%
Customer Concentration Risk [Member] \| Net Product Sales [Member] \| Customer One [Member]
Concentration risk percentage		22.00%	18.00%	17.00%
Customer Concentration Risk [Member] \| Net Product Sales [Member] \| Customer Two [Member]
Concentration risk percentage		11.00%	10.00%	12.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member]
Concentration risk percentage			22.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Two [Member]
Concentration risk percentage			15.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Three [Member]
Concentration risk percentage			13.00%	10.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member]
Concentration risk percentage				17.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Two [Member]
Concentration risk percentage				11.00%
Customer Concentration Risk [Member] \| Purchases [Member] \| Vendor One [Member]
Concentration risk percentage	23.00%	63.00%	35.00%	45.00%
Customer Concentration Risk [Member] \| Purchases [Member] \| Vendor Two [Member]
Concentration risk percentage	12.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Vendor One [Member]
Concentration risk percentage			36.00%	63.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Vendor Two [Member]
Concentration risk percentage			17.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Vendor Three [Member]
Concentration risk percentage				14.00%

XML 33 R22.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Apr. 30, 2021	Jul. 31, 2020
Accounting Policies [Abstract]
Raw materials	$ 23,000	$ 17,000
Finished goods	545,000	530,000
Inventory, net	$ 568,000	$ 547,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
Debt (Details Narrative) - USD ($)	Apr. 30, 2021	Apr. 30, 2021	Apr. 30, 2020
Net proceeds from payroll protection program loan		$ 239,000
California Bank and Trust [Member] \| Payroll Protection Program [Member]
Net proceeds from payroll protection program loan	$ 239,000
Debt description	The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs.
Debt instrument interest percentage	1.00%	1.00%
Debt instrument term	2 years

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative)			3 Months Ended	9 Months Ended
Stockholders' Equity (Details Narrative)	Mar. 09, 2020 USD ($) $ / shares shares	Oct. 02, 2019 USD ($) $ / shares shares	Apr. 30, 2020 USD ($)	Apr. 30, 2021 USD ($) $ / shares shares	Apr. 30, 2020 USD ($)	Jan. 31, 2021 $ / shares shares	Jul. 31, 2020 $ / shares shares
Common stock, shares authorized \| shares				150,000,000		150,000,000	150,000,000
Common stock, par value \| $ / shares				$ 0.01		$ 0.01	$ 0.01
Value of common stock shares			$ 2,000,000		$ 2,830,000
Number of warrants outstanding \| shares				327,765
Warrant expiration date				Jan. 23, 2022
Warrant intrinsic value				$ 0
Minimum [Member]
Warrant exercise price \| $ / shares				$ 1.25
Maximum [Member]
Warrant exercise price \| $ / shares				$ 1.28
Private Placement [Member]
Value of common stock shares		$ 830,000
Number of common stock shares issued \| shares		2,862,068
Price per share \| $ / shares		$ 0.29
Proceeds from issuance of private placement		$ 830,000
Private Placement [Member] \| Tom Y Lee [Member]
Investments amount	$ 650,500	290,000
Private Placement [Member] \| Dale Okuno [Member]
Investments amount	450,000	$ 250,000
Private Placement [Member] \| Accredited Investors [Member]
Value of common stock shares	$ 2,000,000
Number of common stock shares issued \| shares	6,896,551
Price per share \| $ / shares	$ 0.29
Proceeds from issuance of private placement	$ 2,000,000
Discount rate on closing price, percentage	0.20
Private Placement [Member] \| Ivan Chen [Member]
Investments amount	$ 52,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended
Share-Based Compensation (Details Narrative) - USD ($)	Jan. 31, 2021	Feb. 29, 2016	Apr. 30, 2021	Apr. 30, 2020	Jul. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period			1 year 11 days
Number of units, vested			500,000
Unrecognized non-cash compensation costs			$ 205,000
Options issued to purchase common stock exercisable			7,059,125
Weighted average exercise price			$ 0.88
Weighted average contractual term			4 years 8 months 5 days
Share-based compensation			$ 621,000	$ 382,000
2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period		10 years
Common stock shares increase under the plan		4,000,000
Share-based compensation, expiration date		Feb. 04, 2026
Number of shares available for issuance under the plan			483,000
2017 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period	10 years
Common stock shares increase under the plan	5,000,000
Share-based compensation, expiration date	Jan. 31, 2031
Number of shares available for issuance under the plan			5,321,000
Options issued to purchase common stock exercisable			624,375
Number of common stock shares issued			150,190
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average contractual term of expected to vest			5 years
Number of stock option authorized for issuance			60,000
Fair value of stock option			$ 48,000
Terms of award			The options vest quarterly over one year and carry a five year term.
Restricted Stock Unit Awards (RSU's) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period			2 years
Compensation cost recognized			$ 211,000
Number of units, unvested			2,012,500		2,012,500
Number of units, vested			1,512,500
Restricted stock units vested description			These RSUs are issued upon settlement date which is defined as "for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee's Service ceases for any reason and such cessation constitutes a "separation from service" within the meaning of Section 409A of the Code; (iii) the date of Grantee's death or (iv) the date of a Change in Control that constitutes a "change in control event" within the meaning of Section 409A of the Code".
Number of units, granted
Unrecognized non-cash compensation costs			$ 165,000
Restricted Stock Unit Awards (RSU's) [Member] \| Vested and Issuable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of units, vested			1,512,500
Weighted-average contractual term of expected to vest			2 years
Restricted Stock Unit Awards (RSU's) [Member] \| Henry R. Lambert [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized			$ 162,000
Stock issued during period, shares, share-based compensation			400,000
Restricted Stock Unit Awards (RSU's) [Member] \| Shares Vested During Period [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized			$ 62,000	$ 49,000
Restricted Stock Unit Awards (RSU's) [Member] \| Consultants and Others [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period			10 years

XML 37 R26.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Restricted Stock Activity (Details) - Restricted Stock Unit Awards (RSU's) [Member]	9 Months Ended
	Apr. 30, 2021 shares
Outstanding, Beginning balance	2,012,500
Granted
Issued
Forfeited
Outstanding, Ending balance	2,012,500

XML 38 R27.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Restricted Stock Activity (Details) (Parenthetical)	9 Months Ended
	Apr. 30, 2021 shares
Number of units, vested and issuable	500,000
Restricted Stock Unit Awards (RSU's) [Member]
Number of units, vested and issuable	1,512,500

XML 39 R28.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Stock Option Activity (Details) - 2017 Equity Incentive Plan [Member]	9 Months Ended
	Apr. 30, 2021 USD ($) $ / shares shares
Options Outstanding Shares, Beginning Balance \| shares	9,432,875
Options Granted, Shares \| shares	60,000
Options Exercised, Shares \| shares	(624,375)
Options Expired, Shares \| shares	(450,000)
Options Cancelled, Shares \| shares	(400,000)
Options Outstanding Shares, Ending Balance \| shares	8,018,500
Weighted- Average Exercise Price Outstanding, Beginning Balance \| $ / shares	$ 0.88
Weighted- Average Exercise Price Granted \| $ / shares	1.30
Weighted- Average Exercise Price Exercised \| $ / shares	0.88
Weighted- Average Exercise Price Expired \| $ / shares	1.10
Weighted- Average Exercise Price Cancelled \| $ / shares	1.19
Weighted- Average Exercise Price Outstanding, Ending Balance \| $ / shares	$ 0.86
Aggregate Intrinsic Value Outstanding, Beginning Balance \| $	$ 5,255,000
Aggregate Intrinsic Value Outstanding, Exercised \| $	170,000
Aggregate Intrinsic Value Outstanding, Expired \| $	33,000
Aggregate Intrinsic Value Outstanding, Ending Balance \| $	$ 401,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Fair Value Assumptions (Details)	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Share-based Payment Arrangement [Abstract]
Volatility	104.93%	79.48%
Risk-free interest rate	0.18%	1.46%
Dividend yield	0.00%	0.00%
Expected life	2 years 9 months 22 days	5 years 6 months

XML 41 R30.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	Apr. 30, 2021	Jul. 31, 2020	Apr. 30, 2020
Accounts payable	$ 557,000	$ 1,344,000
Harmony Bioscience, Inc [Member]
Accounts payable			$ 124,000
Board Fees due to Officers and Directors [Member]
Accounts payable	$ 63,600		$ 60,000

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 105 245 1 false 40 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://purebio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://purebio.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://purebio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://purebio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) Sheet http://purebio.com/role/StatementsOfOperationsParenthetical Condensed Consolidated Statements of Operations (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://purebio.com/role/StatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://purebio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Basis of Presentation Sheet http://purebio.com/role/BasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Liquidity Sheet http://purebio.com/role/Liquidity Liquidity Notes 9 false false R10.htm 00000010 - Disclosure - Significant Accounting Policies Sheet http://purebio.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Recent Accounting Pronouncements Sheet http://purebio.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 11 false false R12.htm 00000012 - Disclosure - Debt Sheet http://purebio.com/role/Debt Debt Notes 12 false false R13.htm 00000013 - Disclosure - Stockholders' Equity Sheet http://purebio.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 00000014 - Disclosure - Share-Based Compensation Sheet http://purebio.com/role/Share-basedCompensation Share-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions Sheet http://purebio.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://purebio.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://purebio.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://purebio.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://purebio.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables 18 false false R19.htm 00000019 - Disclosure - Share-Based Compensation (Tables) Sheet http://purebio.com/role/Share-basedCompensationTables Share-Based Compensation (Tables) Tables http://purebio.com/role/Share-basedCompensation 19 false false R20.htm 00000020 - Disclosure - Liquidity (Details Narrative) Sheet http://purebio.com/role/LiquidityDetailsNarrative Liquidity (Details Narrative) Details http://purebio.com/role/Liquidity 20 false false R21.htm 00000021 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details 21 false false R22.htm 00000022 - Disclosure - Significant Accounting Policies - Schedule of Inventories (Details) Sheet http://purebio.com/role/SignificantAccountingPolicies-ScheduleOfInventoriesDetails Significant Accounting Policies - Schedule of Inventories (Details) Details 22 false false R23.htm 00000023 - Disclosure - Debt (Details Narrative) Sheet http://purebio.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://purebio.com/role/Debt 23 false false R24.htm 00000024 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://purebio.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://purebio.com/role/StockholdersEquity 24 false false R25.htm 00000025 - Disclosure - Share-Based Compensation (Details Narrative) Sheet http://purebio.com/role/Share-basedCompensationDetailsNarrative Share-Based Compensation (Details Narrative) Details http://purebio.com/role/Share-basedCompensationTables 25 false false R26.htm 00000026 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Activity (Details) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfRestrictedStockActivityDetails Share-Based Compensation - Schedule of Restricted Stock Activity (Details) Details 26 false false R27.htm 00000027 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Activity (Details) (Parenthetical) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfRestrictedStockActivityDetailsParenthetical Share-Based Compensation - Schedule of Restricted Stock Activity (Details) (Parenthetical) Details 27 false false R28.htm 00000028 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activity (Details) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfStockOptionActivityDetails Share-Based Compensation - Schedule of Stock Option Activity (Details) Details 28 false false R29.htm 00000029 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Details) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfFairValueAssumptionsDetails Share-Based Compensation - Schedule of Fair Value Assumptions (Details) Details 29 false false R30.htm 00000030 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://purebio.com/role/RelatedPartyTransactions 30 false false All Reports Book All Reports pure-20210430.xml pure-20210430.xsd pure-20210430_cal.xml pure-20210430_def.xml pure-20210430_lab.xml pure-20210430_pre.xml http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true ZIP 47 0001493152-21-014404-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-014404-xbrl.zip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end